Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Non-Current Assets (2018 - 2025)

Historic Non-Current Assets for Dr Reddys Laboratories (RDY) over the last 14 years, with Q3 2025 value amounting to $3.0 billion.

  • Dr Reddys Laboratories' Non-Current Assets rose 1568.4% to $3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year increase of 1568.4%. This contributed to the annual value of $2.8 billion for FY2025, which is 6999.4% up from last year.
  • As of Q3 2025, Dr Reddys Laboratories' Non-Current Assets stood at $3.0 billion, which was up 1568.4% from $2.8 billion recorded in Q1 2025.
  • Dr Reddys Laboratories' 5-year Non-Current Assets high stood at $3.0 billion for Q3 2025, and its period low was $1.4 billion during Q3 2023.
  • Its 5-year average for Non-Current Assets is $1.9 billion, with a median of $1.6 billion in 2021.
  • As far as peak fluctuations go, Dr Reddys Laboratories' Non-Current Assets crashed by 821.84% in 2022, and later surged by 8210.5% in 2024.
  • Over the past 5 years, Dr Reddys Laboratories' Non-Current Assets (Quarter) stood at $1.6 billion in 2021, then dropped by 6.95% to $1.4 billion in 2022, then dropped by 1.31% to $1.4 billion in 2023, then skyrocketed by 82.11% to $2.6 billion in 2024, then rose by 15.68% to $3.0 billion in 2025.
  • Its last three reported values are $3.0 billion in Q3 2025, $2.8 billion for Q1 2025, and $2.6 billion during Q3 2024.